Table 3

Summary of Phase II clinical trials of PZA

Tumor typeNo. of patientsDose scheduleResponsesRef. no.
Cervical squamous carcinoma21750 mg/m2None 18
3-h i.v.; every 3 wks
Metastatic colorectal cancer14750 mg/m2None 20
3-h i.v.; every 3 wks
Cisplatin-refractory germ cell tumors600 mg/m2None 21
3-h i.v.; every 3 wks
Unresectable or metastatic transitional cell carcinoma14750 mg/m2None 22
3-h i.v.; every 3 wks
Advanced renal cell carcinoma12750 mg/m2None 23
3-h i.v.; every 3 wks
Hormone-refractory prostate cancer17750 mg/m21 24
3-h i.v.; every 3 wks
Advanced pancreatic carcinoma15750 mg/m2None 25
3-h i.v.; every 3 wks
Recurrent platinum-sensitive ovarian cancer42750 mg/m21 CRa; 9 PR 17
3-h i.v.; every 3 wks
Recurrent platinum-resistant ovarian cancer24750 mg/m21 CR; 1 PR 15
3-h i.v.; every 3 wks
Persistent or recurrent endometrial carcinoma23750 mg/m21 PR 16
3-h i.v.; every 3 wks
Advanced colorectal carcinoma15750 mg/m2None 26
3-h i.v.; every 3 wks
Pediatric solid tumorsb47640 mg/m2None 19
3-h i.v.; every 3 wks
  • a CR, complete response; PR, partial response.

  • b This included children with rhabdomyosarcomas (n = 8), Ewing’s Family Tumors (n = 10), neuroblastomas (n = 7), osteogenic sarcomas (n = 8), Wilms’ tumor (n = 2), and other solid tumors (n = 12) [except brain tumors].